ACM
NRIX icon

Accent Capital Management’s Nurix Therapeutics NRIX Stock Holding History

Accent Capital Management’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$8.8K Buy
568
+188
+49% +$3.12K ﹤0.01% 212
2025
Q4 		$7.21K Buy
380
+310
+443% +$4.45K ﹤0.01% 243
2025
Q3 		$647 Sell
70
-180
-72% -$1.87K ﹤0.01% 371
2025
Q2 		$2.85K Buy
+250
New +$2.7K ﹤0.01% 372

Other funds holding NRIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

Accent Capital Management's NRIX Position: Q1 2026 in Review

Accent Capital Management increased its Nurix Therapeutics (NRIX) stake by 49% in Q1 2026, buying an estimated $3.12K and bringing the position to 568 shares worth $8.8K. The position accounts for ﹤0.01% of the portfolio, ranked #212.

Accent Capital Management first reported a position in NRIX in Q2 2025 and has held it in 4 quarters since. 195 funds tracked by Wall St. Rank hold NRIX as of Q1 2026.

  • Accent Capital Management held 568 shares of Nurix Therapeutics worth $8.8K as of Q1 2026.
  • Accent Capital Management bought 188 Nurix Therapeutics shares in Q1 2026, an estimated $3.12K.
  • Nurix Therapeutics made up ﹤0.01% of Accent Capital Management's portfolio in Q1 2026, its #212 holding.
  • Accent Capital Management first reported a position in Nurix Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • 195 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q1 2026.

Based on Accent Capital Management's 13F filing for Q1 2026, filed 11 May 2026.